HUGEL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208,000 KRW | +0.73% |
|
+4.05% | +39.22% |
| Mar. 27 | Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. | CI |
| Mar. 27 | Hugel, Inc. authorizes a Buyback Plan. | CI |
| Sales 2024 * | 383B 278M | Sales 2025 * | 444B 323M | Capitalization | 2,270B 1.65B |
|---|---|---|---|---|---|
| Net income 2024 * | 106B 76.96M | Net income 2025 * | 136B 98.74M | EV / Sales 2024 * | 4.77 x |
| Net cash position 2024 * | 442B 321M | Net cash position 2025 * | 520B 378M | EV / Sales 2025 * | 3.94 x |
| P/E ratio 2024 * |
22.9
x | P/E ratio 2025 * |
17.8
x | Employees | 562 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 45.95% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.73% | ||
| 1 week | +4.05% | ||
| Current month | +8.84% | ||
| 1 month | +13.35% | ||
| 3 months | +31.31% | ||
| 6 months | +50.29% | ||
| Current year | +39.22% |
1 week
203 000.00
213 500.00
1 month
182 200.00213 500.00
Current year
147 100.00219 000.00
1 year
99 700.00219 000.00
3 years
99 700.00279 500.00
5 years
99 332.34279 500.00
10 years
55 499.45279 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sun-Ho Han
COO | Chief Operating Officer | 59 | 17-12-31 |
Dong-Hoon Oh
CTO | Chief Tech/Sci/R&D Officer | 52 | 14-06-30 |
Chang-Jin Lee
CTO | Chief Tech/Sci/R&D Officer | 52 | 13-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Suk-Yong Cha
CHM | Chairman | 70 | 23-03-29 |
| 50 | - | ||
Han-Soo Keyoung
BRD | Director/Board Member | 50 | 22-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.39% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.36% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 208,000 | +0.73% | 34 907 |
| 24-04-25 | 206,500 | -0.72% | 38,184 |
| 24-04-24 | 208,000 | +0.97% | 35,089 |
| 24-04-23 | 206,000 | -1.44% | 34,865 |
| 24-04-22 | 209,000 | +3.21% | 51,615 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
208,000
KRW
Average target price
218,778
KRW
Spread / Average Target
+5.18%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.22% | 1.64B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -18.95% | 29.48B | |
| +57.86% | 25.43B | |
| -17.81% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- A145020 Stock
